NCT05446584 · Phase 2 · RECRUITING

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

This trial is testing whether a history of mild traumatic brain injury (concussion) plays a role in the biological changes seen in amnestic mild cognitive impairment. The tool being used is HD-tDCS, a non-invasive brain stimulation device that delivers a weak electrical current through the scalp. Researchers will also analyze blood biomarkers. This is a Phase 2 study, meaning it is exploring how something works, not proving a treatment is effective.

You may qualify if

  • Active diagnosis of amnestic mild cognitive impairment
  • Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample
  • Female and male subjects
  • All races/ethnicities
  • Age 55 years and older
  • Fluent in English

You're excluded if

  • Mild traumatic brain injury within past year
  • Lifetime history of moderate or severe brain injury
  • Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor)
  • Lifetime major cardiovascular conditions (e.g., heart attack, heart failure)
  • Current substance use disorder
  • Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder)
  • Current vision or hearing impairment that interferes with testing
  • Any electronic and or metallic implants in the skull or brain
  • Current medication use known to alter HD-tDCS reactivity

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-05-04

View full record on ClinicalTrials.gov

All APOE4 clinical trials